Luye Pharma (HKG:2186) secured Macao government's approval to market toludesvenlafaxine hydrochloride extended-release tablets, according to a Monday filing with the Hong Kong bourse.
The drug, branded Ruoxinlin, is indicated for major depressive disorder, the filing said.
Phase 3 study results showed the drug reduces anxiety, retardation, fatigue, and anhedonia or lack of interest, promotes social functions, and improves cognition, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.